This panel provides drug-protein interaction and their ADRs along with references
| Toxicity |
Interacting Protein |
Mechanism |
Reference |
| Cutis Laxa | Collagen (P02452) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited, which results in cutis laxa [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Cutis Laxa | Elastin (P15502) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited@ which results in cutis laxa. [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| D-Penicillamine Toxic Reactions | HLA class I histocompatibility antigen B-8 (P30460) | HLA-B8 was found at a higher frequency in patients with proteinuria and other types of renal involvement of D-penicillamine toxic reactions. [ ADR Type 5 ] | HLA-A,-B, and -DR antigens in relation to GOld and D-penicillamine toxicity in Greek patients
|
| D-Penicillamine Toxic Reactions | HLA class II histocompatibility antigen DRB1-1 (P04229) | The lowest frequency of side-effects was seen in patients with HLA-DR1 and DR2 of D-penicillamine toxic reactions [ ADR Type 5 ] | HLA-A,-B, and -DR antigens in relation to GOld and D-penicillamine toxicity in Greek patients
|
| D-Penicillamine Toxic Reactions | HLA-DR3 (Q29887) | HLA-DR3 had a higher frequency in patients with D-penicillamine toxic reactions. [ ADR Type 5 ] | HLA-A,-B, and -DR antigens in relation to GOld and D-penicillamine toxicity in Greek patients
|
| D-Penicillamine Toxic Reactions | MHC class II HLA-DR2 (Q29787) | The lowest frequency of side-effects was seen in patients with HLA-DR1 and DR2 of D-penicillamine toxic reactions. [ ADR Type 5 ] | HLA-A,-B, and -DR antigens in relation to GOld and D-penicillamine toxicity in Greek patients
|
| Dermatopolymyositis | HLA-DR4 (O77963) | The high prevalence of the B18, B35, DR4 haplotype in these patients denotes immunogenetic differences with primary DPM patients (B8-DR3) and DP-induced myasthenia (DR1),which attribute to the Dermatopolymyositis induced by D-penicillamine in rheumatoid polyarthritis [ ADR Type 3 ] | Dermatopolymyositis and D-penicillamine: value of the search for anti-JO1 antibodies
|
| Dermatopolymyositis | MHC class I antigen (O19755) | The high prevalence of the B18, B35, DR4 haplotype in these patients denotes immunogenetic differences with primary DPM patients (B8-DR3) and DP-induced myasthenia (DR1),which attribute to the Dermatopolymyositis induced by D-penicillamine in rheumatoid polyarthritis. [ ADR Type 3 ] | Dermatopolymyositis and D-penicillamine: value of the search for anti-JO1 antibodies
|
| Dermatopolymyositis | MHC class I antigen HLA-B18 (O77967) | The high prevalence of the B18, B35, DR4 haplotype in these patients denotes immunogenetic differences with primary DPM patients (B8-DR3) and DP-induced myasthenia (DR1),which attribute to the Dermatopolymyositis induced by D-penicillamine in rheumatoid polyarthritis. [ ADR Type 3 ] | Dermatopolymyositis and D-penicillamine: value of the search for anti-JO1 antibodies
|
| Elastosis Perforans Serpiginosa | Collagen (P02452) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited, which results in elastosis perforans serpiginosa. [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Elastosis Perforans Serpiginosa | Elastin (P15502) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited@ which results in elastosis perforans serpiginosa. [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Embryopathy | Collagen (P02452) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited, which results in embryopathy. [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Embryopathy | Elastin (P15502) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited@ which results in embryopathy [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Polymyositis | HLA class II histocompatibility antigen DRB1-1 (P04229) | The cumulative dose responsible for the DPA-induced polymyositis (PM) case amounted to 465 g. All the patients were HLA DR1. [ ADR Type 1 ] | Neuromuscular disorders associated with D-penicillamine treatment for rheumatoid arthritis
|
| Skin Toxic Reactions | HLA-DRB3 02 01 class II antigen beta III (Q6LBW5) | Skin manifestations of D-penicillamine toxic reactions were mainly associated with the presence of HLA-DRw6 [ ADR Type 5 ] | HLA-A,-B, and -DR antigens in relation to GOld and D-penicillamine toxicity in Greek patients
|
| Thin And Vulnerable Skin | Collagen (P02452) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited, which results in thin and vulnerable skin. [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Thin And Vulnerable Skin | Elastin (P15502) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited@ which results in thin and vulnerable skin [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Wound Healing Defects | Collagen (P02452) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited, which results in wound healing defects [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|
| Wound Healing Defects | Elastin (P15502) | D-penicillamine (DPA) leads to side effects in different ways:collagen and elastin crosslinking are inhibited@ which results in wound healing defects [ ADR Type 5 ] | D-penicillamine--side effects, pathogenesis and decreasing the risks
|